The Online Investor
Satsuma Pharmaceuticals Inc (STSA)

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered by a proprietary pre-filled, single-use, nasal delivery device.
Company Name: 
Satsuma Pharmaceuticals Inc
Website: 
www.satsumarx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding STSA: 
13
Total Market Value Held by ETFs: 
$2.83M
Total Market Capitalization: 
$151.00M
% of Market Cap. Held by ETFs: 
1.87%
Quotes delayed 20 minutes



Buy (2.67 out of 4)
16th percentile
(ranked lower than approx. 84% of all stocks covered)

Analysts' Target Price:
STSA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Satsuma Pharmaceuticals Inc (STSA) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.